JUL 24, 2015 02:58 PM PDT

Radiotherapy-Resistant Tumors

By discovering how micro-RNAs, small regulatory molecules in cells, render prostate cancer resistant to radiotherapy, researchers at the University of York in the United Kingdom believe that they can develop more effective prostate cancer treatments. Such treatments would enable the use of lower doses of chemotherapy while being effective and potentially saving the lieves of thousands of men. Prostate cancer, the most commonly diagnosed form of male cancer in the UK, takes the lives of more than 11,000 men every year, according to an article in Drug Discovery News (http://www.dddmag.com/news/2015/07/scientists-discover-why-some-prostate-cancer-tumors-are-radiotherapy-resistant?et_cid=4692171&et_rid=45505806&type=cta).
University of York scientists try for a better way to treat prostate cancer.
According to the National Cancer Institute (NCI), prostate cancer is the most common nonskin cancer and the second leading cause of cancer-related death in men in the United States. NCI estimated that, in 2014, 233,000 men would be diagnosed with prostate cancer in the US, and nearly 29,500 men would succumb to the disease. Prostate cancer incidence rates in the United States began to increase dramatically in the late 1980s with the widespread use of the prostate-specific antigen (PSA) test to detect prostate cancer. During the 1990s both incidence and mortality rates for prostate cancer have declined (http://www.cancer.gov/research/progress/snapshots/prostate).

As published in European Urology and the British Journal of Cancer, scientists at the YCR Cancer Research Unit in the Department of Biology at York have established a direct connection between the micro-RNA molecules and radiotherapy resistance. Each cell has micro-RNAs that control the gene expression. They are involved in the organization of various tissues in the body, telling genes when and where to be active. According to the York scientists, micro-RNAs act as the switch that enables cells to react quickly to changes in their environment, such as a dose of chemotherapy.

According to previous research, all prostate cancers have at least four different cell types, including the cancer stem cells that resist most current treatments. When the York researchers looked at the micro-RNAs in each of the cell types individually, they discovered that some micro-RNAs acted in a positive manner, switching off genes which could make the stem cells susceptible to radiotherapy. Other micro-RNAs were not expressed in the resistant stem cells, enabling the expression of resistance genes. If the levels of these micro-RNAs in the clinic can be manipulated in the clinic, it could be possible to kill greater numbers of cancer stem cells, addressing the issue that 30 percent of prostate cancer patients have a recurrence of their tumors after radiotherapy.

As Professor Norman Maitland, of the YCR Cancer Research Unit, summarized, "Doctors don't know which patients are going to relapse - and the reason they relapse is probably because the radiotherapy is not focused on the stem cell; it is focused on the whole tumor. By exploiting this new knowledge, we can make radiotherapy more effective. It could extend the lifetime of these men. It could also allow a lower dose of radiotherapy to be used, and that's really what we are testing at the moment. This will be the bridge to transforming that into a treatment and making radiotherapy better."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAY 30, 2018
Cannabis Sciences
MAY 30, 2018
Cannabinoid Receptor Role in Inhibition of Renal Cell Carcinoma
Researchers investigated the potential connections between the endocannabinoid system and tumor cell growth inhibition in renal cell carcinoma....
JUL 24, 2018
Cancer
JUL 24, 2018
FDA Approves New Drug for Refractory/Relapsed AML
A new drug and new drug class have been approved by the FDA for relapsed or refractory AML patients with an IDH1 mutation. The new drug offers options for patients....
JUL 30, 2018
Cancer
JUL 30, 2018
Challenges Coming to a Cancer Diagnosis in the UK
England's NHS Cancer Patient Experience Survey shows some cancers take longer for GPs to recognize....
AUG 14, 2018
Cancer
AUG 14, 2018
Using Arsenic to Enhance Cancer Therapies Beyond Leukemia
An already existing combination of arsenic and all-trans retinoic acid is found to inhibit a key signaling pathway that exerts broad effect on oncogenic processes for some solid tumors....
AUG 15, 2018
Cancer
AUG 15, 2018
Cancer Control Headway in The Last 20 Years
Learning from history and what changes have been made will continue to help drive cancer controls for the future....
SEP 04, 2018
Cancer
SEP 04, 2018
Glyphosate "herbicides" as a carcinogen
You may have heard of glyphosate as it is a chemical that is approved to be used in herbicides. But did you know that it could lead to cancer!!...
Loading Comments...